Heather M. Schneider

Partner

New York
Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, NY 10019-6099
T 212 728 8685
F 212 728 9685
hschneiderwillkie.com

Heather M. Schneider is a partner in the Intellectual Property Department. Heather’s practice focuses on patent litigation, as well as antitrust issues involving intellectual property. Her litigation experience encompasses an array of technologies, including pharmaceuticals and biologic products, computer software, medical devices, and chemical products. Her practice also includes client counseling on patent issues, as well as intellectual property issues associated with transactional work including licensing, mergers, and bankruptcy.

In the pharmaceutical field, Heather has played a significant role in litigations and appeals for major life sciences companies involving drug products including: oxycodone HCI (OxyContin), erythropoietin (Epogen), dexmedetomidine (Precedex), rotigotine (Neupro), fingolimod (Gilenya), paricalcitol (Zemplar), argatroban (Argatroban Injection), and amlodipine besylate (Norvasc). In the computer field, Heather appeared before the U.S. and Canadian courts in the Nortel bankruptcy litigation involving the allocation of proceeds from the sale of Nortel’s $4.5 billion portfolio of telecommunications patents. She has also worked on patent litigation and antitrust issues involving standard-essential patents in the chemical industry.

+ Continue Reading

Heather M. Schneider is a partner in the Intellectual Property Department. Heather’s practice focuses on patent litigation, as well as antitrust issues involving intellectual property. Her litigation experience encompasses an array of technologies, including pharmaceuticals and biologic products, computer software, medical devices, and chemical products. Her practice also includes client counseling on patent issues, as well as intellectual property issues associated with transactional work including licensing, mergers, and bankruptcy.

Selected Significant Matters

  • Confidential Matters – Currently evaluating biologics-related patents for companies developing biosimilars, including patents directed to proteins, cell culture media, polynucleotides, vectors, host cells, and production methods.
  • Amgen v. Hospira (erythropoietin) – Trial counsel in first jury trial under the BPCIA, which resulted in a split decision on patent infringement, validity, and Safe Harbor issues.
  • Purdue v. Amneal (oxycodone HCl) – Counsel for appellees Amneal and Kashiv Pharma, LLC defending multiple IPR decisions invalidating OxyContin patents.
  • AbbVie v. Hospira (paricalcitol) – Trial counsel in U.S. District Court victory for Hospira in patent infringement case. Court ruled that Hospira’s generic paricalcitol product does not infringe AbbVie’s U.S. patent, ending multi-year litigation.
  • Hospira and Orion v. Sandoz (Precedex) – Trial counsel in district court judgment protecting the validity and enforceability of the patent for the active ingredient in the sedative Precedex.
  • In re Nortel Networks – Trial counsel for UK pension plan in unprecedented joint US/Canadian bankruptcy trial, addressing allocation of proceeds from the sale of Nortel’s $4.5 billion portfolio of telecommunications patents. Received favorable trial decisions from the Delaware and Canadian courts, case settled on appeal.
  • Arkema v. Honeywell – Represent chemical company in declaratory judgment action seeking to invalidate patents directed to 1234yf, a hydrofluorocarbon used in automobile refrigeration.
  • CryptoPeak v. Commonwealth and Forethought – Obtained dismissal in one case and settlement in another for companies accused of infringing internet cryptography patents.

Selected Professional and Business Activities

  • Heather is an Officer and Board Member of the New York Intellectual Property Law Association where she is Secretary of the association and liaison to the Young Lawyer’s Committee.
  • In 2017, Heather obtained a Certificate in Genetics and Genomics from the Stanford University Center for Professional Development, where she completed courses in genetics, personal genomics, gene therapy, genetic engineering, and biotechnology.
  • Prior to attending law school, Heather worked as a Senior Technical Consultant for Hewlett-Packard. She is co-author of the book Mobile Applications: Architecture, Design, and Development (Prentice Hall 2004).

Selected Publications and Lectures

  • PTAB Developments Involving CRISPR-Cas9 Gene Editing Technology, with M. Johnson, NYIPLA, The Report (April/May 2017).
  • “RAND” or “FRAND” Royalties: Considerations After Microsoft v. Motorola, with E. Chang and S. Lombardi, ABA Section of Antitrust Law, The Antitrust Counselor, Vol. 7.3 (June 2013).
  • Frequently Asked Antitrust Questions, Chapter on Antitrust & Intellectual Property with D. Park and J. Lucena-Pichardo, ABA Section of Antitrust Law (2d Ed. April 2013).
  • NYIPLA, Patent/Antitrust Concerns Arising in Corporate Transactions (Jan. 16, 2014)
  • Hot Topics at the Intersection of Intellectual Property and Antitrust (Sept. 30, 2014; Apr. 20, 2015; Feb. 17, 2016)
  • Mobile Applications: Architecture, Design & Development, with V. Lee and R. Schell, Prentice Hall PTR Books (April 2004).

Publications / News / Events